The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
March 7th 2024
The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
AKR1C3 Expression May Hold Potential as a Biomarker, Clinical Target in T-ALL
April 24th 2022Aldo-keto reductase 1C3 (AKR1C3) has been identified as a potential biomarker and target in several cancers, and a recent study found it to be a potential biomarker in T acute lymphoblastic leukemia/lymphoma (T-ALL).
Read More
Neurocognitive Changes After CAR T-Cell Therapy for NHL Similar to Other Cancers
April 20th 2022With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.
Read More
City of Hope’s Alvarnas: Payers Must Recognize Cancer Care Is Different
April 17th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.
Read More
Pretreatment PROs May Have Survival Implications in DLBCL, Finds Exploratory Study
April 12th 2022The researchers found that the prognostic values for both overall and progression-free survival remained even after adjusting for the International Prognostic Index, a widely used prognostic model of outcomes for the disease.
Read More
Nearly One-Fourth of DLBCL Cases May Be Attributable to Obesity in Young Adulthood, Says Study
April 8th 2022Across all measures, researchers found that body mass index in young adults had the strongest association with the risk of non-Hodgkin lymphoma (NHL), estimating that 23.3% of diffuse large B-cell lymphoma (DLBCL) cases and 11% of NHLs overall can be attributed to obesity.
Read More
High CD47 Expression on HRS Cells Carries Poor Survival Implications in Classical HL
March 27th 2022Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.
Read More
FDA Accepts sNDA for Zanubrutinib to Treat CLL/SLL
February 23rd 2022The supplemental new drug application (sNDA) filing includes data from 2 pivotal randomized phase 3 global studies, ALPINE and SEQUOIA, of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The target action date is October 22, 2022.
Read More
Study Evaluates Impact of AE Severity on Health State Utility for CAR T Treatment in LBCL
February 9th 2022Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.
Read More
Incyte Withdraws FDA Submission for Parsaclisib for FL, MZL, MCL
January 27th 2022Incyte has become the latest company to pull an FDA filing following Gilead and Secura Bio, which both voluntarily withdrew therapies that had been granted accelerated approval but hadn’t completed confirmatory studies for full approval.
Read More
Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT
January 12th 2022While acute lymphoblastic leukemia (ALL) was still the primary cause of death, researchers saw a steady increase in 2-year survival from 27.8% to 54.8% even as patient age at the time of relapse after allogeneic hematopoietic stem cell transplantation (HCST) increased.
Read More